Targeted Therapy with Nanatinostat and Valganciclovir in Recurrent EBV-positive Lymphoid Malignancies: a Phase 1b/2 Study.
Blood advances（2023）
摘要
Key Points • Nanatinostat plus valganciclovir is a novel oral regimen for relapsed/refractory EBV+ lymphoma that warrants further investigation.• Encouraging efficacy and safety were observed across a variety of EBV+ lymphoma subtypes.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要